Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.


Antibodies that target the immune checkpoint receptor programmed cell death protein 1 (PD-1) have resulted in prolonged and beneficial responses toward a variety of human cancers. However, anti-PD-1 therapy in some patients provides no benefit and/or results in adverse side effects. The factors that determine whether patients will be drug sensitive or… (More)
DOI: 10.1172/JCI84940


  • Presentations referencing similar topics